Replies to post #174069 on Biotech Values

[DewDiligence]

It’s better than 50/50, IMO, that FDA says something about MNTA’s ANDA on or before the patent-expiration date. But the FDA is under no obligation to do so, which is I used the word, likely rather than a stronger adjective.